Frankfurt
23.10.26 | 08:04
0,174 Euro
-4,51 % -0,008
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | IRLAB Therapeutics: Nomination Committee Appointed for IRLAB's Annual General Meeting 2027 | 221 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 20, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that... ► Artikel lesen | |
| Di | IRLAB Therapeutics: IRLAB's Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal | 247 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / October 20, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA),... ► Artikel lesen | |
| 09.10. | IRLAB Therapeutics: IRLAB to present at Redeye Theme: Neurology | 292 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 24.09. | IRLAB Therapeutics: IRLAB Appoints Janne Backman as New Chairman of the Board | 395 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 24, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel... ► Artikel lesen | |
| 03.09. | IRLAB Therapeutics: IRLAB's CEO Intends to Step Down During the First Quarter of 2027 | 368 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / September 3, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announces today that... ► Artikel lesen | |
| IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.08. | New Number of Shares and Votes in IRLAB Therapeutics AB | 367 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 31, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During August 2026, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB" or the... ► Artikel lesen | |
| 26.08. | IRLAB Therapeutics AB Ser. A Q2 Loss Narrows | 1 | RTTNews | ||
| 26.08. | IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - June 2026 | 499 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 20.08. | IRLAB Therapeutics: IRLAB: Invitation to The Interim Report for Q2 2026 Presentation and Webcast | 372 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 20, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the... ► Artikel lesen | |
| 19.08. | IRLAB Therapeutics: IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO | 338 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / August 19, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company... ► Artikel lesen | |
| 31.07. | New Number of Shares and Votes in IRLAB Therapeutics AB | 376 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 31, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During July 2026, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB" or the "Company")... ► Artikel lesen | |
| 30.06. | Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB | 421 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 30, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB held its Annual General Meeting today, Tuesday 30 June 2026, at Biotech center in... ► Artikel lesen | |
| 29.06. | IRLAB Therapeutics AB: IRLAB's rights issue was oversubscribed and the company resolves on allotment in the overallotment issue | 239 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
| 16.06. | IRLAB Therapeutics: IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies | 395 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 16, 2026 / IRLAB Therapeutics AB ((STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that... ► Artikel lesen | |
| 10.06. | Listing of subscription rights and paid subscription shares of IRLAB Therapeutics AB | 317 | GlobeNewswire | With effect from June 11, 2026, the subscription rights of IRLAB Therapeutics AB will be traded on the list for Equity rights. Trading will continue up until and including June 22, 2026.
... ► Artikel lesen | |
| 05.06. | Report from the Extraordinary General Meeting of IRLAB Therapeutics AB | 415 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 5, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB held its Extraordinary General Meeting today, Friday, 5 June 2026.The following main... ► Artikel lesen | |
| 05.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 05.06.2026 | 761 | Xetra Newsboard | Das Instrument 6IRA SE0012675361 IRLAB THERAP. AB A EQUITY wird cum Kapitalmassnahme gehandelt am 05.06.2026 und ex Kapitalmassnahme am 08.06.2026 The instrument 6IRA SE0012675361 IRLAB THERAP. AB A... ► Artikel lesen | |
| 03.06. | IRLAB Therapeutics: IRLAB Participates at Aktiedagarna in Stockholm on June 9 | 370 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 3, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announces that CEO Kristina... ► Artikel lesen | |
| 06.05. | IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - March 2026 | 531 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 6, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the... ► Artikel lesen | |
| 30.04. | IRLAB Therapeutics: Invitation to the Interim Report for Q1 2026 Presentation and Webcast | 443 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 30, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GSK | 22,650 | -0,83 % | GSK: Lungenkrebsmittel in weltweiter Studie mit positiven Daten | DJ GSK: Lungenkrebsmittel in weltweiter Studie mit positiven Daten
Von Adria Calatayud
DOW JONES--GSK hat mit einem einlizenzierten Lungenkrebsmedikament positive Ergebnisse erzielt. Bei der... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| BAYER | 43,960 | -0,57 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | ||
| OMNIAB | 4,770 | -0,21 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| BRIGHT MINDS BIOSCIENCES | 52,50 | -0,36 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| MERCK KGAA | 143,95 | -1,64 % | Merck kauft Silence Therapeutics - Hoffnungsträger gegen seltenen Blutkrebs | Der Darmstädter Pharma- und Technologiekonzern Merck will das britische Biotechnologie-Unternehmen Silence Therapeutics übernehmen und dafür rund 1,3 Milliarden Dollar zahlen. Beide Unternehmen haben... ► Artikel lesen | |
| NOVO NORDISK | 35,350 | +0,58 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| DERMAPHARM | 38,500 | -0,52 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| APNIMED | 18,540 | +0,05 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen |
Das Unternehmen IRLAB THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,174 Euro und damit -4,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IRLAB THERAPEUTICS AB finden Sie auf Wallstreet Online.